Inhibition of varicella-zoster virus (VZV) replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) has been examined in vitro under various experimental conditions. The 50% inhibitory dose (ID50) of BVDU for VZV replication in human embryonal fibroblast (HEF) cultures was 0.016 jig/ ml, if the assay was based on the reduction of visible foci. If the assay was based on the reduction of immunofluorescent foci, the ID50 was 3 times higher. There was no significant difference in ID50, whether the HEF cultures were infected with cell-free or cell-associated VZV. When the HEF cells were infected with VZV at different multiplicities of infection (MOI), the ID50 of BVDU increased in parallel with the increase of MOI. BVDU was normally added immediately after virus infection. However, the addition of BVDU could be delayed until 8 hr after infection without substantial decrease of activity. On the other hand, BVDU did not cause any inhibition of focus formation when it was removed within 8 hr after VZV infection. If removed at 24 or 48 hr after infection, BVDU caused a significant reduction in focus formation. BVDU had no effect on focus formation if added to the HEF cells before virus infection. BVDU was also found to inhibit VZV focus formation in Vero cells, but only at an ID50 that was 5-10 times higher than the ID50 noted in HEF cells. varicella-zoster virus ; antiherpes compound ; tissue culture Varicella-zoster virus (VZV) is the causative agent of chickenpox (varicella), which is the leading infectious disease in infants. VZV frequently persists in sensory ganglia after primary infection, and when it is reactivated, it will give rise to shingles (herpes zoster). Generally, these infections are self-limited and do not lead to complications. However, severe and often fatal VZV infections may occur in immunocompromised patients. Considering the questionable values of zoster immune globulin in the prophylaxis and therapy of such severe VZV infections,
there is a need for effective chemotherapeutic measures.
During the past few years several new antiherpes compounds have been developed (De Clercq 1982b) . One of the most promising is (E)-5-(2-bromovinyl)-2'-deoxyurinine (BVDU) (De Clercq et al. 1979) . Previous investigations have shown that BVDU is a highly potent and selective inhibitor of herpes simplex virus (HSV) type 1 and VZV replications ; it is less active against HSV type 2 (De Clercq et al. 1980c, 1982) . Recently, we have evaluated a series of 20 antiherpes compounds for their ability to inhibit the replication of VZV in human embryonal fibroblast (HEF) cell cultures, and have confirmed that BVDU is one of the potent and selective VZV inhibitors that have been described so far (Shigeta et al. 1983 ). However, inhibition of VZV replication by BVDU can be influenced by several viral and cellular conditions, so that it is difficult to make a strict comparision of anti-VZV activity of BVDU with that of other antiviral compounds which have been assayed under different experimental conditions. We have therefore evaluated the inhibitory effects of BVDU on VZV replication under a variety of viral and cellular conditions. These studies were aimed to establish the ideal assay system for the determination of the anti-VZV activity of BVDU, and to obtain further insight into its mechanism of action. It also intends to the optimal assay conditions for comparative testing of anti-VZV compounds.
MATERIALS AND METHODS

Compound
(E)-5-(2-bromovinly)-2'-deoxyuridine (BVDU) was synthesized by Dr. R. Busson and Prof. H. Vanderhaeghe at the Rega Institute (Leuven) and was dissolved at a concentration of 10 pg/ml in phosphate buffered solution (PBS), pH 7.2. The solution was frozen at -20C C until use.
Cells
Human embryonic fibroblast (HEF) cells and Vero cells were grown in Eagle's minimal essential medium (MEM) supplemented with 10% fetal calf serum (FCS), 100 units/ml of penicillin G, and 50 ,u g/ml of streptomycin.
Virus strain and preparation of cell free and cell-associated virus The CaQu strain of VZV, which was kindly provided by N. J. Schmidt (Viral and Rickettsial Disease Laboratory, Berkeley, California, USA), was employed throughout all experiments.
Cell-free virus was obtained by sonic treatment of infected cells, following method described by Schmidt and Lennette. (1976) . In brief, HEF cell monolayers were infected at a multiplicity of infection (MOI) of 0.2, and incubated for 36 hr at 36°C. The cells were then suspended into SPGA solution (0.218 M sucrose, 0.0038 M KH2PO4, 0.0049 M Naglutamate, 1% bovine albumin) by using solid glass beads. The cell suspension was then treated with an ultrasonic disrupter (Tomy UR 200-P Tomy Seiko Co., Tokyo) at an intensity of 20 kc/s for 30 sec, and clarified by centrifugation at 2,000 rpm for 10 min. The supernatant served as the cell-free virus stock. It was stored at -80°C until use.
To obtain cell-associated virus, HEF cell monolayers were infected at a MOI of 0.2 and incubated for 3 to 4 days 36°C, until viral pathogenic effect reached 90%. The cells were then washed with PBS and treated with 0.01% trypsin in PBS. The trypsinized cells were collected by centrifugation at 1.500 rpm for 15 min, suspended in growth medium containing 10% dimethyl sulfoxide, and frozen at -80°C until used.
Antiviral assays
The anti-VZV effects of BVDU were examined by monitoring the reduction of both visible and immunofluorescent foci. The former procedure was carried out with confluent HEF monolayers in Linbro multiwell plates with 24 flat bottom wells of 16 mm diameter (Flow Laboratories). REF monolayers were usually infected with approximately 100 plaque forming units (PEU) of virus/well and exposed to varying concentrations of BVDU (0.4, 0.08, 0.016, 0.0032,ug/ml) in maintenance medium (MEM, 2% FCS and antibiotics at the concentrations mentioned above). The monolayers were incubated at 3TC for 3 to 4 days, and, upon removal of the medium, stained with 0.5% crystal violet. Foci of VZVinfected cells appeared as dark blue, while uninfected HEF cells remained light blue. The number of foci was counted under a magnifying glass.
The immunofluorescent procedure was carried out with confluent REF and Vero cell monolayers on Lab-Tek tissue culture slides (8-chambers, Miles Co., USA). The cells were infected with approximately 40 PFU of cell-free VZV chamber and exposed to varying concentrations of BVDU in maintenance medium. After a 2-day incubation period, the cells were fixed in acetone and stained by the indirect immunofluorescent technique, using a human anti-VZV convalescent serum and a rabbit anti-human IgG immunoglobulin conjugated with fluorescein isothiocyanate (Dekopatts a/s, Denmark). The number of foci was counted with a fluorescent microscope (Nikon Co., Tokyo).
With both procedures, antiviral activities are expressed as ID50 (50% inhibitory dose), that is the concentration of compound required to reduce the number of foci by 50%, as compared to the control cell cultures (infected with virus but not exposed to the antiviral compound). All experiments were done three times under the same conditions and the ID50 values correspond to the average values of 3 separete determinations. The antiviral activities were investigated under various experimental conditions, as described in the Results.
RESULTS
Influence of different viral preparations on ID5D of BVDU HEF monolayers were infected with approximately 100 PFU of cell-free virus or cell-associated virus and immediately thereafter exposed to BVDU. The ID50 values of BVDU were similar, whether the HEF monolayers had been infected with cell-free or cell-associated virus, as determined by a visual focus reduction method (Table 1) .
Influence of different cell lines on ID5D of BVDU When Vero cell monolayers were infected with cell-free virus to determine the ID50 of BVDU, it proved too difficult to count visible foci so that in Vero cells only immunofluorescent foci were measured. The ID50 value obtained in Vero cells was 4 times higher than that in HEF cells, if the reduction of immunofluorescent foci was used as a parameter in both cell systems (Table 1) .
Influence of the methods to detect infected cell foci on ID50 of B VDU The ID50 of BVDU in HEF cells as determined by the immunofluorescence method was 3 times higher than that obtained by the visible focus reduction method (Table 1) . This may be due to the fact that not only infected cell foci but also antigen-positive single cells were included in the immunofluorescent focus counts (Fig. 1) . When fluorescent single cells were excluded, the ID50 value was (Table 1) .
Influence of multiplicity of infection (MOI ) on ID50 value of BVDU HEF monolayers were infected with approximately 50 PFU (MOI=0.0001), 500 PFU (MOI = 0.001), and 5,000 PFU (MOI = 0.01) of cell-free virus, and immediately thereafter exposed to BVDU. Visible foci were counted on 3 day after the infection, except for cells infected at a MOI of 0.01. When the cells were infected at a MOI of 0.01, foci were too numerous to count and already fused with each other by 3 days after the infection so that it appeared necessary to count these foci microscopically on 2 day after infection. The results (Fig. 2) show that, as the MOI of VZV increased, the ID50 of BVDU increased proportionally.
Influence of time of addition on ID50 value of BVDU When BVDU was added to HEF monolayers at 1, 2, 4 or 8 hr after infection with cell-free virus, and further incubated for 3 days, it caused a significant inhibition of focus formation. However, the inhibition was weakened if BVDU was added 24 hr after infection. When we counted immunofluorescent foci including immunofluorescent single cells, the ID50 of BVDU was higher than when visible foci were recorded. When immunofluorescent foci and single cells were counted, a decrease in the inhibitory effect of BVDU became already apparent if its addition to the cells was delayed until 4 or 8 hr after infection (Fig. 3) . In another set of experiments BVDU was added to HEF monolayers at different times (2, 8, and 24 hr) before infection. After the BVDU-containing medium was removed the monolayers were washed with control medium, infected with cell-free virus and further incubated at 37°C with contol medium for 3 days, and then the visible foci were counted. Under these conditions BVDU did not inhibit focus formation (data not shown). Thus, pretreatment of the cells with BVDU had no effect on VZV replication. In another experiment, we added various concentrations of BVDU (maximum 0.4 ,u g/ml) to the growth medium, and after the cells had been grown for 3 days in the presence of BVDU they were infected with cell-free virus and further incubated in control medium for 3 days. Again, no effect on VZV replication was noted (data not shown).
Influence of time of removal on ID50 value of BVDU HEF monolayers were infected with cell-free virus and immediately thereafter, exposed to BVDU and further incubated at 3TC. After the incubation of various times (1, 2, 4, 8, 24, and 48 hr), BVDU was withdrawn, and the cells were thoroughly washed and further incubated with BVDU-free medium. The foci were counted 3 or 4 days infection. BVDU did not cause any inhibition when it was removed at 1, 2, 4, or 8 hr after infection (Fig. 4) . However, when it was The arrows indicate that focus formation was not inhibited at the corresponding concentrations of BVDU. removed at 24 or 48 hr after infection, VZV focus formation was suppressed.
Thus, a 1 day contact period with the virus-infected cells appeared necessary for BVDU to the inhibition of VZV replication.
DISCUSSION
In recent years several compounds have been reported to inhibit the replication of VZV in vitro at concentrations which were not toxic for the host cells. These compounds include, among others, acyclovir [9- (Shigeta et al. 1983) . During this study it became evident that the ID50 of the compounds was influenced by various experimental conditions such as the nature of the virus preparation, the multiplicity of infection, the assay method used to detect virus replication, and the time of addition and length of exposure of the antiviral drugs to the cells. The influence of these parameters has now been assessed with BVDU as the antiviral drug.
It is difficult to obtain cell-free VZV of high titer without several passages of the virus in cell culture. This may hamper the rapid examination of anti-VZV activity with newly isolated VZV strains. Therefore, we compared the ID50 values of BVDU for cell-free and cell-associated virus, and found ( Table 1) that cell-associated virus did not markedly differ in its sensitivity to BVDU from cellfree virus.
Immunofluorescence is a useful method to detect small foci that could not be detected by the naked eye. When exposed to a relatively low BVDU concentration (0.08,ag/ml), the infected HEF cell continued to synthesize specific viral antigens, although spreading of virus to uninfected cells was inhibited. At higher BVDU concentrations (i.e. 0.4,ug/ml), synthesis of specific viral antigens was also inhibited. The ID50 values based upon the reduction of immunofluorescent foci were generally higher than those obtained by visible focus reduction (Table 1) . Thus, BVDU appears to prevent the spread of virus at low concentrations (0.08-0.4 ,u g/ml) and to suppress the synthesis of viral antigens at higher concentrations (>0.4pg/ml).
In Vero cells the ID50 value of BVDU for HSV is approximately 10 times higher than that in HEF cells (De Clercq 1982a) . This was also the case for VZV (Table 1) . It is not clear why Vero cells are less responsive to the antiviral potency of BVDU than HEF cells. A possible reason is that BVDU is phos-phorylated at lower efficiency by the virus-induced deoxythymidine kinase (Tk) in Vero cells than in HEF cells. Even among HEF strains established from different materials there must be variation in the ID50 values. In our previous experiment (Shigeta et al. 1983 ), ID50 value for CaQu strain was lower that in this experiment (0.001, ,g/ml).
The anti-VZV activity of BVDU was strictly dependent on the multiplicity of infection. The ID50 of BVDU gradually increased with increasing MOI of VZV (Fig. 2) . A similar dependence of antiviral activity on virus multiplicity has been demonstrated previously with BVDU in primary rabbit kidney cells infected with HSV type 1 (De Clercq et al. 1980b) .
The inhibitory effect of BVDU on VZV focus formation obviously depended on the time of addition and length of exposure of the compound with the virusinfected cells. Even if it was added at 8 hr after infection (Fig. 3) or withdrawn at 24 hr after infection (Fig. 4) , BVDU effectively suppressed focus formation. However, pretreatment of the cells with BVDU did not exhibit an inhibitory effect on focus formation. These results are consistent with those reported by Harmenberg and Wahren (1982) for the inhibition of HSV replication by acyclovir. VZV-induced Tk activity is detected within 20 hr after infection (Kallander et al. 1982) , and this enzyme may be held responsible for the potent and selective anti-VZV activity of BVDU. This would explain why the presence of BVDU during the 8-24 hr postinfection period is critical for its anti-VZV activity. The fact that pretreatment of the cells with BVDU failed to confer any antiviral resistance suggests that BVDU is not phosphorylated by the cellular Tk.
From the data presented we can formulate the following recommendations for determining the inhibitory effects of BVDU and similar antiviral drugs on VZV replication in vitro : (i) Cell-associated virus is equally suitable as cell-free virus ; (ii) HEF cells are more adequate and sensitive than Vero cells ; (iii) VZV focus visualization by staining with 0.5% crystal violet is both simple and accurate, (iv) the MOI should be standardized (i.e. at 50 PFU per 16mm-diameter well) ; and (v) BVDU should be exposed to the cells within 8 hr after infection and not be removed from the cells before 24 hr after infection. 
